Global progress in clinical research on human respiratory syncytial virus vaccines

Ruofan Peng,Chenghao Chen,Qian Chen,Yuwen Zhang,Renjin Huang,Yanjun Zhang,Jianhua Li
DOI: https://doi.org/10.3389/fmicb.2024.1457703
2024-09-02
Abstract:Human respiratory syncytial virus (hRSV) not only affects newborns but also older adults, contributing to a substantial worldwide burden of disease. However, only three approved hRSV vaccines remain commercially available to date. The development of a safe, practical and broad-spectrum vaccine suitable for all age groups remains extremely challenging. Using five different approaches-live-attenuated, recombinant-vector, subunit, particle-based, and mRNA-nearly 30 hRSV vaccine candidates are currently conducting clinical trials worldwide; moreover, > 30 vaccines are under preclinical evaluation. This review presents a comprehensive overview of these hRSV vaccines along with prospects for the development of infectious disease vaccines in the post-COVID-19 pandemic era.
What problem does this paper attempt to address?